Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2018 Earnings Results

Madrigal Pharmaceuticals Misses on EPS, Stock Down 0.67%

Madrigal Pharmaceuticals reported a loss of $0.45 per share, which was in line with expectations, but no revenue figures were disclosed. The stock reacted negatively, declining by 0.67%, likely due to the lack of guidance and concerns raised during the earnings call about market challenges. Investors may be cautious as the company navigates these issues without clear financial projections.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.45	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current market conditions affecting performance. They emphasized their commitment to long-term goals.

Management highlighted the ongoing challenges in the current market environment.

They noted a focus on long-term strategies despite short-term setbacks.

Madrigal Pharmaceuticals Misses on EPS, Stock Down 0.67%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS, Stock Down 0.67%

Key numbers

Management commentary